Serina Therapeutics, Inc.

SER

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001708599

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.0M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress
Inputs computable	5 of 13
Graded from	filings received through Mar 27, 2026 236 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$1.26 2026-11-17; market equity $33.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 25, 2026

We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company's proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in...

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 23.0						
Gross profitability	not computable	32.8%				

latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%			
required facts have no common fiscal period end					
Accruals ratio	(17.9%)	(6.7%)	23.0	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
annual revenue must exceed $100,000					
Solvency, sleeve percentile 84.0					
Altman Z double-prime	(50.64)	0.31	89.8	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	1.71x	2.68x	78.2	781	2025-12-31
Growth and financing, sleeve percentile 39.9					
Revenue growth, three-year compound	not computable	9.6%			
current value must be positive and the base must exceed $100,000					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 5					
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	29.0%	3.2%	15.6	663	2025-12-31
Net share issuance, one year	24.0%	1.6%	64.3	625	2026-03-18

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(60.0%)	(1.7%)	11
Distance from 52-week high	(68.0%)	(30.5%)	16
EBIT to enterprise value	(85.7%)	0.5%	8
Free cash flow yield	(49.7%)	0.5%	14
Book value to price	0.38	0.28	59
Sales to price	0.00	0.36	1
Composite equity issuance, five years	320.4%	13.5%	96
Relative strength against the sector, log excess return	(1.09)	(0.19)	11
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	pass

Cash, filings, liquidity

Cash and equivalents	$19.4M
Operating cash flow, four quarters	-$22.8M
Months of runway	10.2
Days since last periodic filing	6 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$66,985

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$102,000	2023-12-31	2024-03-22	10-K	24-011022
2	assets	us-gaap:Assets	$9.0M	2023-12-31	2025-03-24	10-K	25-000027
3	net income	us-gaap:NetIncomeLoss	-$19.2M	2025-12-31	2026-03-25	10-K	26-000016
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.0M	2025-12-31	2026-03-25	10-K	26-000016
5	assets	us-gaap:Assets	$7.0M	2025-12-31	2026-03-25	10-K	26-000016
6	assets	us-gaap:Assets	$6.7M	2024-12-31	2026-03-25	10-K	26-000016
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.2M	2023-12-31	2025-03-24	10-K	25-000027
8	gross profit	us-gaap:GrossProfit	$21,000	2022-12-31	2024-03-22	10-K	24-011022
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$34,000	2022-12-31	2024-03-22	10-K	24-011022
10	current assets	us-gaap:AssetsCurrent	$6.1M	2025-12-31	2026-03-25	10-K	26-000016
11	current liabilities	us-gaap:LiabilitiesCurrent	$3.6M	2025-12-31	2026-03-25	10-K	26-000016
12	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$63.5M	2025-12-31	2026-03-25	10-K	26-000016
13	operating income	us-gaap:OperatingIncomeLoss	-$24.0M	2025-12-31	2026-03-25	10-K	26-000016
14	book equity	us-gaap:StockholdersEquity	-$37,000	2025-12-31	2026-03-25	10-K	26-000016
15	liabilities	us-gaap:Liabilities	$7.0M	2025-12-31	2026-03-25	10-K	26-000016
16	operating income	us-gaap:OperatingIncomeLoss	-$3.1M	2023-12-31	2025-03-24	10-K	25-000027
17	interest expense	us-gaap:InterestExpense	$4.9M	2023-12-31	2024-03-22	10-K	24-011022
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$130,000	2025-12-31	2026-03-25	10-K	26-000016
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$56,000	2024-12-31	2026-03-25	10-K	26-000016
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$59,000	2025-12-31	2026-03-25	10-K	26-000016
21	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$100,000	2025-12-31	2026-03-25	10-K	26-000016
22	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$19.2M	2025-12-31	2026-03-25	10-K	26-000016
23	income tax	us-gaap:IncomeTaxExpenseBenefit	$18,000	2025-12-31	2026-03-25	10-K	26-000016
24	current assets	us-gaap:AssetsCurrent	$5.7M	2024-12-31	2026-03-25	10-K	26-000016
25	current liabilities	us-gaap:LiabilitiesCurrent	$2.4M	2024-12-31	2026-03-25	10-K	26-000016
26	assets	us-gaap:Assets	$3.2M	2022-12-31	2024-03-22	10-K	24-011022
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,314,159	2026-03-18	2026-03-27	10-K/A	26-000022
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,932,215	2025-03-20	2025-03-24	10-K	25-000027

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.